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Antimycobacterial agentsIn this paper we describe synthesis, structures and some physicochemical properties of 20 isothiazolo-
pyridines 8–13 substituted differently into an isothiazole ring as well as their in vitro antibacterial assays
against Mycobacterium tuberculosis H37Rv, Mycobacterium fortuitum PCM 672 and Propionibacterium
acnes PCM 2400. Compound 13a was found to be the most active derivative against M. tuberculosis
H37Rv, demonstrating 100% growth inhibition of microorganisms in the primary screen (minimum
inhibitory concentration [MIC] 6.25 lg/mL). Nineteen of the prepared compounds were evaluated against
M. fortuitum PCM 672 and P. acnes PCM 2400 and only compounds 9 and 12d exhibited excellent activity
against individual strains of microorganisms with MIC90 <1 lg/mL. The inhibitory action of the remaining
isothiazolopyridines towards the tested strains of the microorganism was low, absent, or a non-linear
correlation prohibited accurate determination of MIC values. Unexpectedly, seven of the remaining iso-
thiazolopyridines tested againstM. fortuitum and P. acnes stimulated growth of the microorganisms in the
range 10–50% or even more (10b) under experimental conditions.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The treatment of mycobacterial infection has become an impor-
tant problem due to emergence of multiple-drug-resistant micro-
organisms towards conventional therapeutic agents. Therefore
there is a need to search for new antimycobacterial drugs with po-
tent bioactivity and low toxicity. The new antimycobacterial
agents are developed by modiﬁcation of existing antimycobacterial
drugs or by development of new classes of compounds. Among
numerous new classes of compounds synthesized for this purpose,
derivatives of bicyclic structures (benzoxazole, benzothiazole,
benzisothiazole, quinolone, quinoxaline) have exhibited promising
results.1–9
One of our research targets is synthesis of isothiazolo[5,4-b]pyr-
idine derivatives for pharmaceutical purposes. We reported that
several 4,6-dimethylisothazolo[5,4-b]pyridines, depending on sub-stitution on the isothiazole ring, have biological activities including
signiﬁcant analgesic10 or anorectic11 effects. Other authors have
also suggested antiaggregatory12 and antiacne action13 of deriva-
tives of isothiazolo[5,4-b]pyridine. Additionally, derivatives of this
system attracted our considerable interest as 7-azaanalogues of
benzisothiazoles, which are cited for their promising activity
against standard strains of Mycobacterium tuberculosis as well as
against mycobacteria isolated from blood of infected patients
(MIC 16–8 lg/mL).3
However, the mechanism of antimycobacterial action of benz-
isothiazoles remain unknown and there is poor knowledge about
the structure–activity relationship which would be useful for ra-
tional projection of new bioactive compounds of this series.
Taking into account the interesting antimycobacterial activity
of benzisothiazoles, a few of our 4,6-dimethylisothiazolo[5,4-
b]pyridines possessing 4-aryl(benzyl)piperazinyl(piperidinyl) sub-
structure linked to the N2 or 3-O-atom of the isothiazolopyridine
through different linkage (Fig. 1; 1 and 2, respectively) and synthe-
sized in connection with another project were additionally tested
against Mycobacterium tuberculosis H37Rv.
By comparing the data concerning antimycobacterial potency
against M. tuberculosis H37Rv within series 1 and 2 it was evident
that insertion of the side chain in the N2 position (series 1) but not
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Figure 1. The general formula of isothiazolopyridines 1 and 2.
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this strain of mycobacterium.14,15 The most active compounds
1a–d (Table 4) exhibited 100% inhibition of the mycobacteria after
application at 6.25 lg/mL under preliminary testing.
The aim of this study was synthesis and evaluation under pre-
liminary in vitro antibacterial screening of several classes of new
isothiazolo[5,4-b]pyridines designed specially as potential antimy-
cobacterial agents.
The new series of antimycobacterial isothiazolopyridines in-
clude derivatives with 4-nitrophenylpiperazine grouping in the
structure of the side chain (8, 9; Scheme 1), because such a substi-
tuent is characteristic for quinoxaline derivatives with signiﬁcant
antimycobacterial activity (MIC<1 lg/mL).6
Pagani et al. revealed that carbamic esters of N2-(2-hydroxy-
ethyl)benzoisothiazole were interesting compounds for their
promising in vitro antimycobacterial results (MIC 16–32 lg/mL).4
In this context we prepared series of isomeric isothiazolopyridines
of carbamic ester type 10 and 11 (Scheme 2).
As reported in the literature, N-alkylbenzylamines are com-
pounds with speciﬁc action against mycobacteria.16 On the other
hand, our N2-hydroxymethylisothiazolopyridine 3 (Fig. 2) showed
65% inhibition ofMycobacterium tuberculosis H37Rv.15 A similar ef-
fect was exhibited by 2-hydroxymethylbenzoisothiazole 4 (Fig. 2).5
Based on these ﬁndings and combining benzylamines and
hydroxymethylisothiazolopyridine 3 we prepared a series of hy-
brid compounds of speciﬁc Mannich base of type 12 as potential
antimycobacterial agents (Scheme 3).
Additionally, to develop the structure–antimycobacterial rela-
tionship, we included in our investigation isomeric isothiazolopyri-
dines 13a and 13b devoid of a base nitrogen atom within the
structure of the side chain (Scheme 4).Compounds 8–13 were
screened against Mycobacterium.
In 1984 and 1985, several patented N-(cyclo)alkyl, hydroxyal-
kyl, (un)substituted benzyl and carbamoylisothiazolo[5,4-b]pyri-
din-3-one compounds were claimed as useful agents against8  n=1
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Scheme 1. Synthetic route of compounds 8 and 9.
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Scheme 3. Synthetic route of compounds 12a–h.Propionibacterium acnes,13 which hydrolyzes sebum triglycerides
to form the fatty acids responsible for inﬂammation in acne. There-
fore all of our new isothiazolopyridines (except 11c) were also
tested against Propionibacterium acnes in order to complete their
in vitro microbiological proﬁle.
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Different synthetic routes were used in preparation of the ﬁ-
nal isothiazolopyridines 8–13 (Schemes 1–4) with satisfactory
yield.
In general, the new compounds were prepared starting from
4,6-dimethylisothiazolo[5,4-b]pyridin-3(2H)-one 7 (Scheme 4) or
its hydroxy(chloro)alkyl derivatives 3, 5, 6 (Scheme 1–3). Interme-
diates 3, 5–7 were described recently.11,17–19
Preparation of the 4-nitrophenylpiperazinylalkyl derivatives of
isothiazolopyridine 8 and 9 involves alkylation of 4-nitrophenyl-
piperazine with corresponding intermediates 3 or 5, respectively
(Scheme 1).
The isomeric carbamates 10a–d and 11a–d were prepared after
treatment of N2- or 3-O-(2-hydroxyethyl)derivatives of isothiazol-
opyridine 6a and 6b, respectively, with appropriate alkyl and phe-
nyl isocyanates (Scheme 2).
Alkylation of the commercially available benzylamines
(un)substituted with different substituents in the o-, m- or p-posi-
tions (X = CH) or 2-aminomethylpyridine (X = N) with excess of
2-hydroxymethylisothiazolopyridine 3 led to formation of the
speciﬁc Mannich bases of type 12 (Scheme 3).
Finally, alkylation of isothiazolopyridine 7 with 2-(2-phen-
oxy)ethoxyethyl chloride afforded the isomeric compounds 13a
and 13b (Scheme 4).
Analytical puriﬁcation of all new products 8–13 (20 com-
pounds) was achieved by crystallization from the appropriate sol-
vent. Final compounds were characterized by a sharp melting
point, correct elemental (C, H, N) analyses, proton or carbon nucle-
ar magnetic resonance (1H NMR, 13C NMR) spectra, and in the case
of 12d by X-ray data.
The structures of the isomeric isothiazolopyridines 13a and 13b
(Scheme 4) were assigned on the basis of 1H NMR. In the N2-substi-
tuted isomer 13a the signal of the methylene protons adjacent to
the N2-nitrogen of the isothiazolopyridine was recorded
3.8 ppm. The 3-O-substitution produced downﬁeld shift of these
protons (4.7 ppm). The above spectral data agree with those pre-
viously reported by us for related isomeric N2- and 3-O-hydroxy-
ethyl substituted intermediates 6a and 6b (Scheme 2),
respectively.
The 1H NMR spectra of compounds 12, independent of the type
and position of R-substitution on the phenyl ring of the benzyl sub-
structure (Scheme 3), showed a 2H singlet 4.0 and 4H singlet
5.0 ppm corresponding to the 2 NCH2N methylene group and
1 arylmethylene group ArCH2N. It may suggest a speciﬁc conﬁg-
uration of these compounds. Therefore the structure of the Man-
nich bases 12 were additionally determined by the X-ray
diffraction method taking into account 12d as a model compound
(Section 2.1.).Most of the compounds 8–13 were highly lipophilic substances
and were characterized by logPcalcd 2.5–6.5 (Table 3). LogPcalcd was
calculated using the ChemPlus program from Hypercube, Inc., IBM
PC version, implemented in the HyperChem program package.
The new synthesized compounds presented above, except for 8
and 9, were tested in vitro for their activity against strains ofMyco-
bacterium tuberculosis (18 compounds), and additionally all com-
pounds 8–13, except for 11c, were evaluated against
Mycobacterium fortuitum and Propionibacterium acnes.2.1. Crystal structure of isothiazolopyridine 12d
The structure of compound 12d was unambiguously conﬁrmed
by X-ray analysis (Fig. 3).
The geometry (bond lengths, angles and planarity) of the iso-
thiazolopyridine rings in 12d is very similar to that found in 4,6-
dimethylisothiazolo[5,4-b]pyridine-3(2H)-one20 and other related
structures containing this ring.21 The N atom of the tertiary amino
group has pyramidal conﬁguration with the sum of angles around
it of 337.2 characteristic for sp3 hybridization. The methylene
bridges linking the isothiazolopyridine and phenyl rings with the
central amino group have the gauche–gauche–trans, gauche–
trans–gauche and trans–gauche–trans conformation in relation to
the isothiazolopyridine rings A and B and phenyl ring C, respec-
tively (Table 1) (see Fig. 4).
The dihedral angles between the mean planes of isothiazolo-
pyridine and phenyl rings are: A/B = 55.74(4), A/C = 32.19(8)
and B/C = 87.72(9). The methoxy group, coplanar with the phenyl
ring, is in trans conformation with respect to the methylene chain
with the torsion angle C31–C32–O37–C38 of 178.1(3). The con-
formation of the molecule as a whole is stabilized by the C–H. . .X
(X = O, N) intramolecular hydrogen bonds listed in Table 2.
The packing of molecules in the crystal structure of 12d (Fig. 3)
is governed by combination of a weak C12–H12C. . .O3A hydrogen
bond linking the inversion-related molecules into dimers and a
C11A–H11D. . .O3A hydrogen bond linking the dimers into molec-
ular chains parallel to the X axis direction (Table 2).
Signiﬁcant p–p interactions observed in the packing form the
pairs of parallel isothiazole S1A. . .C8A rings and pairs of the paral-
lel pyridine N7B. . .C6B rings belonging to inversion-related mole-
cules with the centroid-to-centroid separations of 3.7348(15) and
3.9392(18) Å, respectively.3. Microbiology and discussion
Structures of the compounds evaluated under the microbiolog-
ical study are shown in Table 3.
Initially all compounds, except 8 and 9, were screened against
Mycobacterium tuberculosis H37Rv strain at a single concentration
of 6.25 lg/mL. Rifampicin, an antibiotic known for its potent activ-
ity against many strains of M. tuberculosis, was used as a reference
drug. The microbiological data were provided by the GWL Hansen’s
Disease Center (Colorado State University) within the Tuberculosis
Acquisition and Coordinating Facility (TAACF: NIH, NIAID Contract
AI45264) screening program for the discovery of novel drugs for
treatment of tuberculosis.
All the new compounds, except 11c, were additionally tested for
their in vitro action against Mycobacterium fortuitum PCM 672 as
well for Propionibacterium acnes PCM 2400 obtained from the Pol-
ish Collection of Microorganisms (PCM). Isoniazid or erythromycin,
respectively, were used as reference drugs.
The results of antibacterial studies of isothiazolopyridines 8–13
with the data for the control drugs are presented in Table 3.
To develop the preliminary S-A relationship, microbiologically
tested compounds 8–13 were divided into four series (Table 3):
Figure 3. A view of the X-ray molecular structure of 12d with the atomic labeling scheme (probability 50%).
Table 1
Selected torsion angles ()
Torsion angle Torsion angle
S1A–N2A–C12A–N21 72.1(3) S1B–N2B–C12B–N21 52.7(3)
N2A–C12A–N21–C12B 72.7(3) N2B–C12B–N21–C12A 153.6(2)
N2A–C12A–N21–C22 159.4(2) N2B–C12B–N21–C22 78.9(3)
C32–C31–C22–N21 164.0(2) C31–C32–O37–C38 178.1(3)
C31–C22–N21–C12A 81.5(3)
C31–C22–N21–C12B 149.8(2)
Figure 4. The molecular packing in crystal of 12d. Dashed lines indicate intermo-
lecular hydrogen bonds [symmetry codes: (i) = 1 + x, y, z; (ii) = 1x, 2y, z)].
Table 2
Hydrogen-bond geometry (Å, ) for 12d
D–H. . .A D–H H. . .A D. . .A D–H. . .A
C12A–H12C. . .O3A 0.97 2.46 2.850(3) 104
C10B–H10F. . .O3B 0.96 2.33 3.085(6) 135
C12B–H12F. . .O3B 0.97 2.51 2.879(4) 102
C36–H361. . .N21 0.93 2.50 2.843(4) 102
C11A–H11D. . .O3A(i) 0.96 2.57 3.512(4) 166
C12A–H12C. . .O3A(ii) 0.97 2.44 3.258(4) 142
Symmetry codes: (i) = 1 + x, y, z; (ii) = 1x, 2y, z.
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bearing in the structure of the side chain a terminal phenyl ring
separated from the N2-methyleneisothiazolopyridine fragment
with a different spacer (X).
Series (II) N2-substituted carbamates 10, except for 10d, which
was included in series I.
Series (III) 3-O-substituted carbamates 11. In this series 3-O-
isomer 13b was also included.
Series (IV) Speciﬁc Mannich bases of type 12.
The data from Table 3 showed that carbamates 10a–c (series II),
10d (series I) and 11 (series III), which represent a group of com-
pounds related to the antimycobacterial benzisothiazoles,4 in con-
trast to their precursors, were completely inactive against
Mycobacterium tuberculosis H37Rv.
Similarly, lack of activity against this strain of mycobacterium
was shown by highly lipophilic (logPcalcd 5.5–6.6) Mannich bases
12 (Table 3, series IV), which combine corresponding benzylamines
and two N2-methyleneisothiazolopyridine moieties in a single
molecule.
Signiﬁcant action against Mycobacterium tuberculosis H37Rv
(100% inhibition) was exhibited only by isothiazolopyridine 13a
(Table 3), devoid of a nitrogen atomwithin the structure of the side
chain. At the same time, its 3-O-substituted isomer 13b (Table 3,
series III) was completely inactive under preliminary screening.
The above results correspond with our recent observation within
Table 3
In vitro antibacterial activity against Mycobacterium tuberculosis, Mycobacterium fortuitum, Propionibacterium acnes of isothiazolopyridines 8–13
RN
N
S
CH3
H3C
O
X
No. X R Mycobacterium tuberculosis Mycobacterium
fortuitum
Propionibacterium
acnes
LogPcalcd
MIC50 MIC90 MIC50 MIC90
H37RV MIC 6.25 lg/mL % inhibition (lg/mL) (lg/mL)
Series I
8 N N p-NO2 — 197 0 0 0 4.38
9 N N p-NO2 — 0⁄ 0 <1 <1 4.01
10d
O N
H
O
H 12 0⁄ 0 0 0 2.96
13a O O H 100 nc nc nc nc 2.98
N
N
S
CH3
H3C
O
O R
O
R LogPcalcd
Series II
10a NH CH3 17 nc nc 6.9 0 2.46
10b NH CH3 0 125 0 0 0 2.63
10c
NH CH3
CH3
CH3 0 st nc nc 3.20
R
O
H3C
CH3
S
N
N
R LogPcalcd
Series III
11a
O NH
O
CH3
6 st 184 0 1.58
11b
O NH
O
CH3
0 125 0 st 1.74
11c
O NH
O
CH3
CH3
CH3 16 — — — — 2.31
11d
O NH
O
0 0 0 0 0 2.86
13b O O 0 nc nc 0 0 2.69
R
N
CH3
H3C
N
S
O
N
X
O
S
N
CH3
CH3
N
R X LogPcalcd
Series IV
12a H CH 6 nc nc st 5.93
12b o-Cl CH 0 nc nc 0 0 6.44
12c p-Cl CH 0 nc nc 0 0 6.64
12d o-OCH3 CH 0 <1 <1 38 0 5.67
12e p-OCH3 CH 0 nc nc st 5.67
12f m-OCH3, p-OCH3 CH 8 0⁄ 0 st 5.42
12g 3,4-O(CH2)2O– CH 0 nc nc st 5.61
12h H N 4 nc nc 0⁄ 0 5.01
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Table 3 (continued)
R
N
CH3
H3C
N
S
O
N
X
O
S
N
CH3
CH3
N
R X LogPcalcd
Rifampicin 98 (125 lg/mL)
Isoniazid 0.322 lg/mL >250 lg/mL
Erthromycin <1 lg/mL <1 lg/mL
—Compound not tested.
nc—At the lower concentration the preparation inhibited the growth of microorganisms, at the higher concentration this effect decreased and then increased again.
0—Not active up to 250 lg/mL
0⁄—Bacteriostatic effect against: Mycobacterium fortuitum – 9 (40–46% inh.), 10d (42–50% inh.), 12f (21–32% inh.), Propionibacterim acnes – 12h (36–50% inh.).
st—Compound enhances bacterial replication: Mycobacterium fortuitum within range 10–50%: 10c (max. effect was observed at concentration of 15.6–31.25 lg/mL), 11a
(0.97–250 lg/mL), Propionibacterim acnes within range 10–50%: 12a (15.6 lg/mL), 12e, f (0.97–250 lg/mL), 12g (31.25–62.5 lg/mL); effect >50%: 11b (3.9–15.6 lg/mL).
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isothiazolopyridine 1a (Table 4) exhibited 100% inhibition of
mycobacteria under preliminary screening whereas its O-isomer
(Fig. 1 and 2 (R =m-Cl, n = 2)) was a practically inactive compound.
Because the new isothiazolopyridines 10–12 and 13b exhibited
<20% inhibition in the preliminary screen against M. tuberculosis
H37Rv at the assayed concentration of 6.25 lg/mL, these com-
pounds were not further evaluated.
For compound 13a causing >90% inhibition in the primary
screen at concentration of 6.25 lg/mL a conﬁrmatory advanced
screening was performed against M. tuberculosis H37Rv in order
to determine an actual MIC. In this investigation we also included
recently synthesized and evaluated isothiazolopyridines 1a–d
(Fig. 1, Table 4), which under preliminary investigation exhibited
signiﬁcant action against M. tuberculosis H37Rv (100% inhibition,
MIC 6.25 lg/mL).14,15 Among these, compound 1b resulted in the
most inhibiting effect, with an MIC value of 1.56 lg/mL. For the
remaining compounds MIC values were 6.25 lg/mL. So, the above
results showed that none of the investigated compounds exhibited
higher activity than that of rifampicin and the most interesting
compound was 12-fold less active than the reference drug,
which showed an inhibition activity of 98% at a concentration of
0.125 lg/mL.
On the other hand, the signiﬁcant inhibitory activity of 13a,
whose N2-substituent structure represents a marked departure
from those present in piperazine (piperidine) derivatives 1a–dTable 4
Antimycobacterial activity against M. tuberculosis H37Rv and cytotoxic activity of isothiaz
N
N
S
CH3
H3C
O
No. X R Mycobacterium tuberculosis H37RV % inhi
1a N N m-Cl 100
1b N N
OH
m-CF3 100
1c N
OH
H 100
1d
N N
O
H 100
13a O O H 100
Rifampicin 98(Table 4), suggests that the nature of the central linkage X within
series I (Table 3) does not play a relevant role in antimycobacterial
activity.
The balance of the therapeutic versus toxicological effects of
bioactive agents is an important parameter when verifying their
applicability as drugs. Therefore the most active isothiazolopyri-
dines 1a–d and 13a were also tested in VERO cells for determina-
tion of cytotoxicity (IC50) and the selectivity indexes (SI), deﬁned as
IC50/MIC. All compounds demonstrate a degree of cytotoxicity
ranging from 1.6 to 7 lg/mL and a low level of selectivity index
SI = 0.25–2.69 (Table 4). The value of SI <10 indicates signiﬁcant
cytotoxicity, and these compounds were not considered to be eval-
uated further against Mycobacterium tuberculosis.
To determine whether the activity of isothiazolopyridines 1a–d
was exclusive toMycobacterium tuberculosis H37Rv, compounds 1a
and 1b were also tested against Mycobacterium avium, a naturally
drug-resistant opportunistic pathogen, using clarithromycin as a
standard. The tested compounds proved inactive after application
at a concentration of 12.5 lg/mL, whereas clarithromycin exhib-
ited inhibition of 98% of microorganisms at a concentration of
2 lg/mL.
Some authors suggest that activity against the rapidly growing
and less hazardous microorganism Mycobacterium fortuitum may
be used as a measure of anti-M. tuberculosis action.3 To verify this
hypothesis, our new isothiazolopyridines 8–13 (except for 11c)
were also evaluated against this strain of microorganisms in vitroolopyridines 1a–d and 13a
R
X
b. MIC (lg/mL) IC50 VERO cells (lg/mL) Selectivity index SI IC50/MIC
6.25 3.3 0.53
1.56 4.2 2.69
6.25 1.6 0.25
6.25 7.0 1.12
6.25 4.1 0.68
0.125 68
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terium fortuitum activity studies are presented in Table 3. Initially
the MIC50 values were determined. Isoniazid was used as a stan-
dard drug (MIC50 = 0.322 lg/mL). The data from Table 3 showed
that only Mannich base 12d signiﬁcantly reduced growth of micro-
organisms and this effect was observed for concentration below
1 lg/mL, similar as for the reference drug. It should be noted that
isothiazolopyridine 12d was also active against M. fortuitum at
MIC90 <1 lg/mL, and this compound will be the subject of further
investigation to conﬁrm the preliminary results.
The fact that very similar analogs 12 of isothiazolopyridine 12d
did not inhibit mycobacteria suggests that a speciﬁc interaction
may exist between compound 12d and some components speciﬁc
for the Mycobacterium fortuitum strain.
The action of the remaining isothiazolopyridines against Myco-
bacterium fortuitum was generally poor, with MIC50 values of
125 lg/mL for carbamates 10b and 11b and 197 lg/mL for nitro-
phenylpiperazine derivative 8. In this context it should be noted
that isothiazolopyridines 9, 10d and 12f were not active against
Mycobacterium fortuitum at the MIC50 level; however, these com-
pounds inhibited growth of 20–50% of microorganisms at all con-
centrations used. Thus, these isothiazolopyridines exhibited
predominantly a bacteriostatic effect.
Taking into account the fact that the new isothiazolopyridines
tested were inactive in general against M. fortuitum as well as
against M. tuberculosis H37Rv, it is difﬁcult to conclude whether
the in vitro anti-M. tuberculosis H37Rv activity of our compounds
can be related to their anti-M. fortuitum action.
The results of an initial in vitro microbiological evaluation of
nineteen of our isothiazolopyridines against Propionibacterium
acnes revealed that four of them (9, 10a, 11a, 12d) were efﬁcient
antibacterial agents at the MIC50 level (Table 3). However, only 9
showed strong activity and produced >90% inhibition of microor-
ganisms (MIC90 >1 lg/mL). Compound 9 also demonstrated higher
activity at the concentration range of 1–0.25 lg/mL when com-
pared to the reference drug (erythromycin).22
Studies are currently ongoing to explain the mode of unique ac-
tion of 9 against Propionibacterium acnes. It should be noted that
isothiazolopyridine 12h inhibited 21–32% of microorganisms at
all concentrations used. Thus, the compound has a bacteriostatic
effect against Propionibacterium acnes.
The remaining isothiazolopyridines tested were inactive
against Mycobacterium fortuitum and Propionibacterium acnes
(0, Table 3), non-linear correlations prohibited accurate determi-
nation of MIC values (nc, Table 3) or unexpectedly 7 of them
(carbamates 10c, 11a, b and Mannich bases 12a, e, f, g)
stimulated bacterial growth (st, Table 3). The compounds
which stimulated growth of microorganisms were classiﬁed as
high stimulating (stimulation >50%) and low stimulating
(stimulation 10–50%) agents. However, it is unclear whether
the low increase in bacterial replication 10% is a consequence
of enhancement of bacterial growth by the preparations or a
lack of activity of the compounds to allow the natural growth
of the microorganisms.
A low growth stimulation effect (10–50%) of the Mycobacterium
fortuitum strain was shown by carbamates 10c and 11a. Compound
11a stimulated at all concentrations used (0.97–250 lg/mL)
whereas 10c exhibited the best stimulation effect within the range
of 15.6–31.25 lg/mL (Table 3).
The best stimulant of Propionibacterium acnes was carbamate
11b, which exhibited the effect of stimulation >50% observed at a
concentration of 3.9–15.6 lg/mL. Mannich bases 12a, e, f, g have
been found to stimulate growth of this strain of bacteria in the
range of 10–50% at different concentrations (Table 3).
In this context of bacterial growth stimulation by compounds
11 and 12, it should be noted that carbamates, like Mannich bases,are unstable substances and it cannot be ruled out that nitrogen-
containing products of degradation of the side chain may be uti-
lized by microorganisms to increase growth stimulation.
4. Conclusion
To investigate the inﬂuence of the introduction of various sub-
stituents in the isothiazolopyridine nucleus on antibacterial activ-
ity, twenty compounds 8–13 were synthesized and in vitro
microbiologically evaluated, including activity against Mycobacte-
rium tuberculosis H37Rv, Mycobacterium fortuitum PMC 672 and
Propionibacterium acnes PCM 2400.
We found that the most active againstMycobacterium tuberculo-
sis H37Rv, compound 13a and isothiazolopyridines 1 (Table 4) re-
cently investigated in this test, were characterized by MIC values
within the range 1.56–6.25 lg/mL (Table 3). However, this activity
was about 10–50 times lower than that observed for the reference
drug rifampicin (0.125 lg/mL). Additionally, these compounds
were characterized by a low value of the selectivity index (SI
0.25–2.69) and therefore they could not be considered for further
evaluation. The investigation also proved rather low anti-Mycobac-
terium fortuitum activity of the tested compounds 8–13, because
only derivative 12d produced 90% reduction of this microorganism
at concentration <1 lg/mL. Only compound 9 exhibited signiﬁcant
activity against Propionibacterium acnes (MIC90 <1 lg/mL). The
activity of 9 was better than that of erythromycin within the con-
centration range of 1–0.25 lg/mL. Unexpectedly, 7 of the 19 iso-
thiazolopyridines tested against M. fortuitum and P. acnes
stimulated growth of microorganisms in the range of 10–50% or
even more (11b).
The promising isothiazolopyridines 9 and 12d will be subjected
to advanced biochemical investigation.5. Experimental
5.1. Chemistry
5.1.1. Chemical experimental section
Melting points were determined with a Mel-Temp II apparatus
(Laboratory Devices, USA) and were uncorrected. The 1H NMR and
13C NMR spectra were recorded on a Bruker 300 MHz spectrometer
in CDCl3 using tetramethylsilane (TMS) as an internal reference
(chemical shift in d ppm). The IR (KBr) spectra were recorded on
a Specord-75 IR Spectrometer. Elemental C, H, N analyses were
run on a Carlo Erba NA-1500 analyzer. The results were within
±0.4% of the values calculated for the corresponding formulae.
Chromatographic separations were performed on a silica gel [Kie-
selgel 60 (70–230 mesh), Merck] column (CC). Progress of the reac-
tion was monitored by TLC on silica gel plates with ﬂuorescent
indicator (Fluka) and visualized by UV light at 254 nm.
5.1.1.1. 2-[4-Nitrophenyl(piperazinyl)methyl]-4,6-dimethyliso-
thiazolo[5,4-b]pyridin-3(2H)-one 8. To a stirred mixture of
2.4 mmol of 2-hydroxymethyl-4,6-dimethylisothiazolo[5,4-b]pyri-
din-3(2H)-one 3 in 20 mL of ethanol 2.4 mmol of 4-nitrophenylpip-
erazine was added. Next the mixture was stirred for 2 h at room
temperature and then reﬂuxed for 5 h. After cooling, the precipi-
tated, crude product was ﬁltered off and crystallized from
methanol.
Mp: 201–203 C, yield: 70%.
IR: 1650 (CO).
1H NMR: 2.60 (s, 3H, CH3), 2.76 (s, 3H, CH3), 2.81–2.97 (m, 4H,
CH2-piperazine), 3.10–3.25 (m, 4H, CH2-piperazine), 4.70 (s, 2H, N–CH2–
N), 6.76 (s, 1H, Hb-pyridine), 6.90–6.99 (m, 2H, ArH), 8.05–8.20 (m,
2H, ArH).
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isothiazolo[5,4-b]pyridin-3(2H)-one 9. To a stirred mixture
of 1.2 mmol of 2-(2-chloro)ethyl-4,6-dimethylisothiazolo[5,4-
b]pyridin-3(2H)-one 5 in 30 mL of ethanol 2.4 mmol of 4-nitrophe-
nylpiperazine was added. Next the mixture was reﬂuxed for 20 h.
After cooling, the solvent was distilled off. The product was iso-
lated from the resulting residue by column chromatography (ethyl
acetate, Rf = 0.61).
Mp: 164–166 C, yield: 37%.
IR: 1650 (CO).
1H NMR: 2.62 (s, 3H, CH3), 2.70–2.85 (m, 9H, CH3 and N(CH2)3),
3.40–3.55 (m, 4H, CH2-piperazine), 4.00–4.25 (m, 2H, Nisothiazole–CH2),
6.76 (s, 1H, Hb-pyridine), 6.85–7.01 (m, 2H, ArH), 8.10–8.25 (m, 2H,
ArH).
13C NMR: 164.9, 163.7, 162.8, 154.7, 149.8, 138.8, 125.9, 122.5,
114.8, 112.9, 56.5, 52.4, 47.0, 40.2, 24.5, 17.5.
5.1.1.3. General procedure for preparation of the isomeric
carbamates 10a–d and 11a–d. To a stirred mixture of a cat-
alytic amount of 1,4-diazabicyclo[2.2.2]octane (DABCO) and
3.75 mmol of appropriate alkyl or phenyl isocyanate in 15 mL of
dry xylene the solution of 2.5 mmol of 2-N- or 3-O-(2-hydroxy-
ethyl) derivatives of isothiazolopyridine 6a and 6b in 10 mL of
dry xylene was added. The reaction mixture was reﬂuxed for 5 h.
Next the solvent was distilled off and the resulting residue was
chromatographed (except for 11b). The obtained, crude product
was crystallized from the appropriate solvent.
2-[2-(N-Ethylcarbamoiloxy)ethyl]-4,6-dimethylisotiazolo[5,4-
b]pyridin-3(2H)-one 10a. Mp: 101–103 C (n-hexane), yield:
54%.
CC (ethyl acetate, Rf = 0.56).
IR: 1660 (CO), 1720 (CO), 3340 (NH).
1H NMR: 1.12 (m, 3H, CH3CH2), 2.59 (s, 3H, CH3), 2.73 (s, 3H,
CH3), 3.16–3.25 (m, 2H, CH3CH2), 4.09 (t, J = 4.8 Hz, 2H, N2–CH2),
4.34 (t, J = 4.8 Hz, 2H, CH2O), 4.86 (br s, 1H, NH), 6.93 (s, 1H, Hb-
pyridine)
2-[2-(N-n-Buthylcarbamoiloxy)ethyl]-4,6-dimethylisothiazol-
o5,4-bpyridin-3(2H)-one 10b. Mp: 79–81 C (cyclohexane),
yield: 61.7%.
CC (ethyl acetate/chloroform 1:1, Rf = 0.54).
IR: 1670 (CO), 1735 (CO), 3420 (NH).
1H NMR: 0.89 (t, J = 7.2 Hz, 3H, CH3CH2CH2CH2), 1.25–1.37 (m,
2H, CH3CH2CH2CH2), 1.40–1.50 (m, 2H, CH3CH2CH2CH2), 2.57 (s,
3H, CH3), 2.71 (s, 3H, CH3), 3.14–3.16 (m, 2H, CH3CH2CH2CH2),
4.07 (t, J = 5.1 Hz, 2H, N2–CH2), 4.32 (t, J = 5.1 Hz, 2H, CH2O), 4.89
(br s, 1H, NH), 6.91 (s, 1H, Hb-pyridine).2-[2-(N-tert-Buthylcarbamoiloxy)ethyl]-4,6-dimehtylisothiaz-
olo5,4-bpyridin-3(2H)-one 10c. Mp: 106–107 C (cyclohex-
ane), yield: 18%.
CC (ethyl acetate/chloroform 1:1, Rf = 0.51).
IR: 1670 (CO), 1730 (CO), 3310 (NH).
1H NMR: 1.31 (s, 9H, C(CH3)3), 2.60 (s, 3H, CH3), 2.75 (s, 3H,
CH3), 4.07 (t, J = 5.2 Hz, 2H, N2–CH2), 4.32 (t, J = 5.1 Hz, 2H,
CH2O), 4.72 (br s, 1H, NH), 6.92 (s, 1H, Hb-pyridine).2-[2-(N-Phenylcarbamoiloxy)ethyl]-4,6-dimethylizothiazol-
o[5,4-b]pyridin-3(2H)-one 10d. Mp: 135–136 C (cyclohex-
ane), yield: 61.3%.
CC (ethyl acetate/chloroform 1:1, Rf = 0.60).
IR: 1670 (CO), 1710 (CO), 3310 (NH).
1H NMR: 2.59 (s, 3H, CH3), 2.73 (s, 3H, CH3), 4.15 (t, J = 5.4 Hz,
2H, N2–CH2), 4.45 (t, J = 5.4 Hz, 2H, CH2O), 4.76 (br s, 1H, NH),6.93 (s, 1H, Hb-pyridine), 7.03–7.08 (m, 2H, ArH), 7.29–7.39 (m, 3H,
ArH).
13C NMR: 164.5, 162.4, 152.8, 137.5, 129.1, 123.7, 122.7, 119.8,
118.9, 63.2, 42.7, 24.2, 17.5.
3-[2-(N-Ethylcarbamoiloxy)ethoxy]-4,6-dimethylisothiazol-
o5,4-bpyridine 11a. Mp: 125–127 C (cyclohexane), yield:
33.8%.
CC (ethyl acetate/chloroform 1:1, Rf = 0.63).
IR: 1690 (CO), 3330 (NH).
1H NMR: 1.12 (m, 3H, CH3CH2), 2.62 (s, 3H, CH3), 2.66 (s, 3H, CH3),
3.05–3.43 (m, 2H, CH3CH2), 4.53 (t, J = 4.8 Hz, 2H, CH2O), 4.68 (t,
J = 4.8 Hz, 2H, OCH2), 4.94 (br s, 1H, NH), 6.93 (s, 1H, Hb-pyridine).
3-[2-(N-n-Butylcarbamoiloxy)ethoxy]-4,6-dimethylisothiazol-
o5,4-bpyridine 11b. Mp: 119–121 C (cyclohexane), yield:
49.4%.
IR: 1690 (CO), 3320 (NH).
1H NMR: 0.91 (t, J = 7.2 Hz, 3H, CH3CH2CH2CH2), 1.01–1.12 (m,
2H, CH3CH2CH2CH2), 1.24–1.48 (m, 2H, CH3CH2CH2CH2), 2.63 (s,
3H, CH3), 2.64 (s, 3H, CH3), 3.09–3.17 (m, 2H, CH3CH2CH2CH2),
4.46 (t, J = 5.2 Hz, 2H, CH2O), 4.66 (t, J = 5.2 Hz, 2H, OCH2), 4.92
(br s, 1H, NH), 6.92 (s, 1H, Hb-pyridine).
3-[2-(N-tert-Buthylcarbamoiloxy)ethoxy]-4,6-dimethylisothiaz-
olo5,4-bpyridine 11c. Mp: 109–111 C (n-heptane), yield:
30.5%.
CC (ethyl acetate/chloroform 1:1, Rf = 0.55).
IR: 1730 (CO), 3260 (NH).
1H NMR: 1.31 (s, 9H, C(CH3)3), 2.62 (s, 3H, CH3), 2.65 (s, 3H,
CH3), 4.42–4.52 (m, 2H, CH2O), 4.64–4.72 (m, 3H, OCH2 and NH),
6.92 (s, 1H, Hb-pyridine).
3-[2-(N-Phenylcarbamoiloxy)ethoxy]-4,6-dimethylisothiazol-
o5,4-bpyridine 11d. Mp: 144–146 C (cyclohexane), yield:
32.8%.
CC (ethyl acetate/chloroform 1:1, Rf = 0.65).
IR: 1740 (CO), 3230 (NH).
1H NMR: 2.61 (s, 6H, 2CH3), 4.64-4.67 (m, 4H, OCH2CH2O), 4.99
(br s, 1H, NH), 6.93 (s, 1H, Hb-pyridine), 7.05–7.37 (m, 5H, ArH).
13C NMR: 160.3, 152.2, 136.8, 128.1, 122.8, 121.0, 118.0, 65.7,
62.1, 24.1, 18.4.
5.1.1.4. General procedure for preparation of benzylamine
derivatives of isothiazolo5,4-bpyridine 12. To a stirred
mixture of 10mmol 2-hydroxymethyl-4,6-dimethylisothiazolo[5,4-b]
pyridin-3(2H)-one 3 in 20mL of ethanol 5mmol of an appropriate
benzylamine was added. Next the mixture was reﬂuxed for 2 h. After
cooling, the precipitated, crude product (12a–c, 12e, 12g) was ﬁltered
off and crystallized from the appropriate solvent. In the case of com-
pounds 12d and 12h–f the ethanol solution was evaporated and the
oil residue was cleaned by crystallization with charcoal from appropri-
ate solvent.
N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-benzylamine 12a. Mp: 192–194 C
(ethanol), yield: 36.7%.
IR: 1670 (CO).
1H NMR: 2.59 (s, 6H, 2CH3), 2.72 (s, 6H, 2CH3), 3.97 (s, 2H,
NCH2), 4.94 (s, 4H, 2N2–CH2), 6.92 (s, 2H, 2Hb-pyridine), 7.22–7.52
(m, 5H, ArH).
N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-2-chlorobenzylamine 12b. Mp: 190–
192 C (ethanol), yield: 45.6%.
IR: 1670 (CO).
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NCH2), 5.00 (s, 4H, 2N2–CH2), 6.90 (s, 2H, 2Hb-pyridine), 7.15–7.36
(m, 4H, ArH).N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-4-chlorobenzylamine 12c. Mp: 162–
164 C (ethanol), yield: 38%.
IR: 1670 (CO).
1H NMR: 2.60 (s, 6H, 2CH3), 2.71 (s, 6H, 2CH3), 3.94 (s, 2H,
NCH2), 4.93 (s, 4H, 2N2–CH2), 6.93 (s, 2H, 2Hb-pyridine), 7.14–7.30
(m, 4H, ArH).
N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-2-methoxybenzylamine 12d. Mp: 178–
180 C (cyclohexane), yield: 28.7%.
IR: 1660 (CO).
1H NMR: 2.57 (s, 6H, 2CH3), 2.70 (s, 6H, 2CH3), 3.80 (s, 3H,
OCH3), 4.06 (s, 2H, NCH2), 4.97 (s, 4H, 2N2–CH2), 6.89 (s, 2H, 2Hb-
pyridine), 7.21–7.51 (m, 4H, ArH).
13C NMR: 165.2, 163.4, 162.8, 157.8, 150.0, 130.7, 128.9, 125.2,
122.4, 120.5, 115.3, 110.4, 61.0, 55.2, 48.7, 24.5, 17.5.
N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-4-methoxybenzylamine 12e. Mp: 152–
154 C (ethanol), yield: 46%.
IR: 1670 (CO).
1H NMR: 2.59 (s, 6H, 2CH3), 2.72 (s, 6H, 2CH3), 3.78 (s, 3H,
OCH3), 3.94 (s, 2H, NCH2), 4.93 (s, 4H, 2N2–CH2), 6.88 (s, 2H, 2Hb-
pyridine), 7.22–7.49 (4H, ArH).
N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-2-(3,4-dimethoxyphenylo)methylamine
12f. Mp: 157–159 C (acetone), yield: 30%.
IR: 1670 (CO).
1H NMR: 2.59 (s, 6H, 2CH3), 2.72 (s, 6H, 2CH3), 2.81–3.10 (m,
4H, NCH2CH2), 3.79 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.97 (s, 4H,
2N2–CH2), 6.70–6.74 (m, 3H, 3ArH), 6.94 (s, 2H, 2Hb-pyridine).N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-3,4-methylenodioxybenzylamine
12g. Mp: 179–181 C (ethanol), yield: 48.5%.
IR: 1650 (CO).
1H NMR: 2.59 (s, 6H, 2CH3), 2.71 (s, 6H, 2CH3), 3.84 (s, 2H,
NCH2), 4.93 (s, 4H, 2N2–CH2), 5.91 (s, 2H, OCH2O) 6.66–7.31 (m,
5H, 2Hb-pyridine and 3ArH).N,N-Bis(4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo5,4-b]pyri-
din-2-ylmethyl)-N-2-pyridylmethylamine 12h. Mp: 181–
183 C (cyclohexane/toluene 1:2), yield: 26.4%.
IR: 1660 (CO).
1H NMR: 2.59 (s, 6H, 2CH3), 2.72 (s, 6H, 2CH3), 4.14 (s, 2H,
NCH2), 5.05 (s, 4H, 2N2–CH2), 7.03 (s, 2H, 2Hb-pyridine), 7.16–7.89
(m, 3H, 2Hb + Hc-pyridine), 8.67–8.77 (m, 1H, Ha-pyridine).5.1.1.5. 2-[2-(2-Phenoxyethoxy)ethyl]-4,6-dimethylisothiazol-
o[5,4-b]pyridin-3(2H)-one 13a and 3-[2-(2-phenoxyethyl)eth-
oxy]-4,6-dimethylisothiazolo[5,4-b]pyridine 13b. To a
solution of sodium ethoxide prepared from 0.1 mol of sodium
and 100 mL of anhydrous ethanol 0.1 mol of phenol and 0.2 mol
of bis(2-chloroethyl)ether were added. The reaction mixture was
reﬂuxed 12 h and then ﬁltered. The solvent was removed and the
oily residue was distilled under reduced pressure. The 136 C/5 mmHg fraction was collected to give 6 g of oily 2-(2-phenoxy)ethoxyethyl
chloride. 0.02 mol of 2-(2-phenoxy)ethoxyethyl chloride were added
to the stirred mixture of 0.01 mol of 4,6-dimethylisothiazolo[5,4-
b]pyridin-3(2H)-one 7 and 0.01 mol of sodium hydride (60% sus-
pension in mineral oil) in 50 mL of anhydrous dimethylformamide
(DMF). The reaction mixture was heated at 100 C for 10 h and the
solvent was distilled off. The isomers 13a and 13b were isolated by
column chromatography (toluene/ethyl acetate – 10:1). Evaporation
fraction of Rf = 0.53 afforded 1.15 g of O-isomer 13b mp: 67–69 C
(n-hexane). Evaporation fraction of Rf = 0.28 gave 0.44 g of N-isomer
13a mp: 59–61 C.
Compound 13a 1H NMR: 2.58 (s, 3H, CH3), 2.72 (s, 3H, CH3),
3.79–3.9 (4H, 2  CH2), 4.02–4.19 (m, 4H, 2  CH2), 6.83–6.99 (m,
4H, 3ArH and Hb-pyridine), 7.16–7.35 (m, 2H, 2ArH).
Compound 13b 1H NMR: 2.62 s (3H, CH3), 2.64 s (3H, CH3),
3.92–4.15 m (6H, OCH2CH2OCH2), 4.63–4.69 m (2H, 3-OCH2),
6.84–6.93 m (4H, 3ArH and Hb-pyridine), 7.18–7.35 (m, 2H, 2ArH).5.2. Crystallography
5.2.1. X-ray structure determinations of 12d
X-ray data of 12d were collected on the Bruker SMART APEX II
CCD diffractometer; crystal sizes 0.21  0.13  0.04 mm, MoKa
(k = 0.71073 Å) radiation, x scans, absorption correction: multi-
scan SADABS,23 Tmin/Tmax = 0.9509/0.9904. The structure was
solved by direct methods using SIR9224 and reﬁned by full-matrix
least-squares with SHELXL97.25 The H atoms were positioned geo-
metrically and treated as riding on their parent C atoms with C–H
distances of 0.93 Å (aromatic), 0.97 Å (CH2) and 0.96 Å (CH3). All H
atoms were reﬁned with isotropic displacement parameters taken
as 1.5 times those of the respective parent atoms. All calculations
were performed using WINGX version 1.64.05 package.26 CCDC-
859050 contains the supplementary crystallographic data for this
paper. These data can be obtained free of charge at www.ccdc.ca-
m.ac.uk/conts/retrieving.html [or from the Cambridge Crystallo-
graphic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ,
UK; fax: +44 (0) 1223 336 033; email: deposit@ccdc.cam.ac.uk].
5.2.1.1. Crystal data of 12d. C26H27N5O3S2, M = 521.65,
monoclinic, space group P21/c, a = 8.2284(3), b = 16.8045(6),
c = 20.1143(6) Å, b = 110.743(1), V = 2601.00(15) Å3, Z = 4, dcalcd =
1.332 Mg m3, F(000) = 1096, l(Mo Ka) = 0.242 mm1, T = 293 K,
21949 measured reﬂections (h range 1.62–19.58), 2282 unique
reﬂections (Rint = 0.026), ﬁnal R = 0.029, wR = 0.078, S = 1.068 for
2013 reﬂections with I >2r(I).
5.3. Pharmacology
5.3.1. In vitro evaluation of antimycobacterial activity against
M. tuberculosis H37Rv
Primary screening was conducted at 6.25 lg/mL against M.
tuberculosis H37Rv in BACTEC 12B medium using the BACTEC 460
radiometric system.27 Compounds causing <90% inhibition in the
primary screen (MIC >6.25 lg/mL) were not considered for further
evaluation. Compounds demonstrating at least 90% inhibition in
the primary screen were re-tested by serial dilution beginning at
the concentration of 6.25 lg/mL to determine the actual minimum
inhibitory concentration (MIC). The MIC is deﬁned as the lowest
concentration inhibiting 99% of the inoculum.
Also, compounds were screened by serial dilution to assess tox-
icity to a VERO cell line (IC50), beginning at 10 MIC if sample sol-
ubility in culture media was permitted. The selectivity index (SI) is
deﬁned as the ratio of the measured IC50 in VERO cells to the MIC
described above.
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Mycobacterium fortuitum
(PCM 672), Staphylococcus aureus (PCM 2602) and Propionibac-
terium acnes (PCM 2400)
5.3.2.1. Bacterial strains and growing conditions. The strains
ofMycobacterium fortuitum (PCM 672) and Staphylococcus aureus (PCM
2602) and Propionibacterium acnes (PCM 2400) (obtained from the Pol-
ish Collection of Microorganisms (PCM) of the Institute of Immunology
and Experimental Therapy, Polish Academy of Sciences) were used
throughout the study. Bacteria were cultivated on liquid 79 culture
medium (for M. fortuitum), Luria–Bertani (LB) medium (for S. aureus)
at 37 C for 24 h under aerobic conditions. Then bacterial cells were di-
luted with the samemedia, respectively, to obtain suspension of about
2 105 cfu/mL of each strain.
5.3.2.2. Antibacterial susceptibility test. The antibacterial
activities of synthesized compounds were determined against bacte-
rial strains by the microplate Alamar Blue assay according to Ahmed
et al.28 Stock solutions of the compounds were prepared in dimethyl
sulfoxide (DMSO) 1mg/mL and were diluted with appropriate media
in the range 0.03–1000 lg/mL on a cell culture microtitration plate. To
the wells containing 100 lL of drug compound, aliquots of 100 lL of
the diluted suspension of the strainwere added. The control wells con-
sisting of either bacteria only or medium only and those containing
different drug concentrations (100 lL) were inoculated with 100 lL
of the diluted bacterial cells. Plates were incubated at 37 C for 48 h
and after that 20 lL of Alamar Blue (10 diluted) and 12.5 lL of
20% Tween 80 solutions were added to the wells and incubation
was continued at 37 C for 2 h. Fluorescence was measured using Vic-
tor apparatus (Wallac, Perkin Elmer). The experiment was repeated
two or three times. The minimal inhibitory concentration (MIC) was
deﬁned as the lowest drug concentration which prevented a color
change from blue to pink, inhibiting the bacterial growth by P90%.
The means and standard error values were determined using the pro-
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